Date: 2016-01-08
Type of information: Series A financing round
Company: Zymeworks (Canada)
Investors: BDC Capital (Canada) Celgene (USA - NJ) CTI Life Sciences Fund (Canada) Eli Lilly (USA - IN) Fonds de solidarité FTQ (Canada) Lumira Capital (Canada) Perceptive Advisors (USA - NY) Teralys Capital (Canada) Northleaf Venture Catalyst Fund (Canada) Brace Pharma Capital (USA - MD) Merlin Nexus (USA - NY)
Amount: $61.5 Million
Funding type: series A financing round
Planned used:
- This financing round will support the advancement of Zymeworks' Azymetric™ therapeutics pipeline and clinical development of Zymeworks’ lead therapeutic candidates, ZW25 and ZW33, which the company plans to move into clinical development later in 2016.
Others:
- • On January 8, 2016, Zymeworks announced the closing of a US$ 61.5 million Series A mezzanine financing to support the advancement of its Azymetric™ therapeutics pipeline. The financing was supported by a syndicate of U.S. and Canadian institutional investors, including all existing institutional and strategic investors. It was co-led by new investors BDC Capital and Lumira Capital, and joined by existing Zymeworks investors Eli Lilly, Celgene, CTI Life Sciences Fund, and the Fonds de solidarité FTQ. New investors in the financing include Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital, Merlin Nexus and others.
- Dion Madsen, Senior Managing Partner in BDC Capital’s Healthcare Venture fund will join Zymeworks’ board of Directors, and Dr. Daniel Hétu, Managing Director in Lumira Capital, will join as an observer. MTS Securities, LLC, an affiliate of MTS Health Partners, and BMO Capital Markets Corp. acted as advisors to Zymeworks in the transaction.
Therapeutic area: Cancer - Oncology
Is general: Yes
